NIKTIMVO® (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2]Australia ...
Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...
Novel conditioning regimen improves survival and engraftment in sickle cell transplant patients with low graft versus host disease rates.
Stem cell transplants for acute leukemia using pooled, non-human leukocyte antigen (HLA)-matched cord blood led to near-perfect engraftment and no severe graft-versus-host disease (GVHD) in a small ...
The addition of an off-the-shelf pooled stem cell product to a single unit of umbilical cord blood conferred favorable ...
On the heels of FDA’s clearance, the company plans to begin a Phase Ib/IIa trial evaluating CK0802 in patients who have ...
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results